Pharmacokinetics in Extracorporeal Membrane Oxygenation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-01

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of the present study is to investigate the risk factors that affect drug pharmacokinetic (PK) during extracorporeal membrane oxygenation (ECMO). To advance understanding of PK variance and improve the patients outcomes during ECMO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Extracorporeal Membrane Oxygenation for Respiratory Failure Patients

NCT06231446

Respiratory Failure Patients Treated With ECMO

RECRUITING

Hemodynamic Comparison of Peripheral and Central VA ECMO.

NCT05669183

Shock, Cardiogenic Cardiac Arrest Extracorporeal Circulation; Complications +1 more

RECRUITING

Pharmacokinetic Alterations During ECMO

NCT01938079

Acute Respiratory Failure

COMPLETED NA

Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS)

NCT01669863

ARDS

COMPLETED PHASE1/PHASE2

Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance

NCT06660784

Tracheal Intubation Extracorporeal Membrane Oxygenation Nitric Oxide +1 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ex vivo experiments for drug stability testing and ECMO circuits testing in animal models.PK studies in healthy animals and critically ill animal models with or without ECMO to define the PK alterations. Clinical PK studies in critically ill patients on ECMO.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Extracorporeal Membrane Oxygenation Pharmacokinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Animal study

Critically ill animal on ECMO. PK data from critically ill animal on ECMO will be compared with data from controls and healthy animal on ECMO.

ECMO

Intervention Type DEVICE

Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure

Clinical study

To describe variation of plasma concentration of drugs in patients receiving ECMO, as compared with patients without ECMO.And develop population PK model for ECMO patients.

ECMO

Intervention Type DEVICE

Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ECMO

Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Extracorporeal membrane oxygenation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are undergoing ECMO for respiratory and or cardiac dysfunction
* Clinical indication for the antibiotics
* Clinical indication for the sedatives and analgesics

Exclusion Criteria

* No consent
* Known allergy to study drug
* Pregnancy
* Massive fluid resuscitation (\>50% blood volume transfused) in the previous 8 hours.
* Therapeutic plasma exchange in the preceding 24 hours

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No